10th Microbiome Movement Summit

Returning for its 10th anniversary, the Microbiome Movement Summit remains the premier global gathering for microbiome drug developers, uniting experts across discovery, preclinical, translational, regulatory, and commercial sectors to drive innovation in the microbiome space.

What's New for 2025?

- Hear Brand New Insights from Industry Trailblazers: Gain key updates from leaders at Ferring Pharmaceuticals, Siolta Therapeutics, MaaT Pharma, and Corundum Systems Biology as they discuss clinical advancements and commercial strategies shaping the future of microbiome therapeutics.

- 11 New Organizations Taking the Stage: Discover the latest contributions from emerging companies such as Azitra, Kanvas Bio, Alveolus Bio, Microviable Therapeutics, Unilever, Mikrobiomik, Jona, Nestle Health Science, and more, with each presenting their innovative approaches and breakthroughs in microbiome research.

- Unlock the Next Wave of Microbiome-Based Drug Development: Explore groundbreaking synthetic biology innovations, AI-driven strain engineering, and advanced bioinformatics tools that are accelerating the discovery and optimization of microbiome-based therapies.

- Advance Clinical Translation and Regulatory Success: Learn how companies are overcoming challenges in CMC, large-scale manufacturing, and regulatory approval, with insights on recent FDA approvals, IND-enabling studies, and global market access strategies.

Connect with over 140+ experts from diverse fields within microbiome R AND D, including representatives from Pulmobiotics, Seres Therapeutics, BiomeBank, and PharmaBiome. Engage in dynamic discussions, forge valuable partnerships, and gain actionable insights that will drive your microbiome research and development forward. This summit is your chance to be at the forefront of microbiome innovation and to collaborate with the brightest minds in the industry.

Speakers: Ada Lam, Researcher Analyst, Beacon Microbiome, Andres Cubillos-Ruiz, Co-Founder and Chief Executive Officer, Florey Biosciences, C. Vivek Lal, Founder, Executive Chairman and CSO, Alveolus Bio, Cheri Ackerman, Co-Founder and CEO, Concerto Biosciences, Christopher Weidenmaier, CSO, Mbiomics, Claire Derlot, Chief Business Officer, Biose Industrie, Claudio Hidalgo Cantabrana, CEO, Microviable Therapeutics, Daniel Couto, Chief Operating Officer, Vedanta Biosciences, David Friend, Chief Scientific Officer, Dare Bioscience Inc., Denise Kelly, Investment Advisor, Seventure Partners, Greg Medlock, Senior Director, R AND D, Vedanta Biosciences Inc, Gregory McKenzie, CEO, Keep Bio, Hervé Affagard, Co-Founder and Chief Executive Officer, Maat Pharma, Jessica Schneider, Chief Scientific Officer, Corundum Systems Biology, Jonathan Scheiman, Co Founder and CEO, FitBiomics, Ken Blount, Chief Scientific Office, Rebiotix Inc., a Ferring Company, Kyle Jacoby, Vice President, Kanvas Biosciences, Leo Grady, Founder and CEO, Jona, Maria Lluch Senar, Co-Founder and Chief Scientific Officer, Pulmobiotics, Mark Smith, Venture Lead, Extract Technology, Matt Henn, Executive Vice Pesident and Chief Scientific Officer, Seres Therapeutics, Nadim Ajami, Executive Director - Scientific Research, The University of Texas MD Anderson Cancer Center, Nikole Kimes, CEO and Founder, Siolta Therapeutics, Patricia del Río, Director of Business Development, Mikrobiomik, Paul Carlson, Principal Investigator, US Food and Drug Administration (FDA), Philip Burnham, Chief Scientific Officer, Kanvas Biosciences, Sam Costello, Chief Executive Officer and Managing Director, Biome Bank, Sarah Tomkovich, Senior Scientist, Nestle Health Science, Shikha Snigdha, Senior Director - Scientific Affairs, Unilever, Sonia Timberlake, R AND D Strategy Consultant, Timberlake and MacIsaac Biopharma Consulting (Formerly Finch Therapeutics), Tim Langridge, Senior Scientist, Vedanta Biosciences Inc, Todd Krueger, President and CEO, AOBiome, Tomas de Wouters, CEO, PharmaBiome, Travis Whitfill, Chief Operating Officer, Azitra